Flutamide Therapy for Advanced Prostatic Cancer: a Phase II Study

Abstract

A non-steroidal antiandrogen (flutamide) was used to treat 17 patients with advanced prostatic cancer. Twelve of 14 patients who had already failed to respond to conventional hormone therapy were dead within 12 mo. of starting flutamide therapy and there was a high incidence of side effects. Of 3 patients who had not received prior hormone therapy, 2 showed an early partial response and 1 showed no evidence of response to therapy.